{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:46:30Z","timestamp":1763037990535,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Imatinib treatment for certain cancers can lead to elevated creatine kinase (CK) levels, potentially indicating muscle injury, and ongoing research aims to understand the correlation between imatinib levels and creatine kinase to assess its impact on treatment response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center observational study involved 76 chronic myeloid leukemia (CML) patients receiving imatinib treatment, focusing on evaluating drug and metabolite levels using liquid chromatography\u2013mass spectrometry (LC\u2013MS-MS) instrumentation. Serum CK and creatine kinase-MB (CK-MB) levels were assessed using Colorimetric kits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CK and CK-MB levels were measured, CK showed a median value of 211.5 IU\/l and CK-MB showed a median value of 4.4 IU\/l. Comparing low and high CK groups, significant differences were found in peak and trough plasma concentrations of imatinib and its metabolites. Correlations between CK levels and pharmacokinetic parameters were explored, with notable associations identified. Binary logistic regression revealed predictors influencing the therapeutic response to imatinib and categorized expected CK levels into high or low, with peak levels of imatinib emerging as a significant predictor for CK level categorization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study highlights the link between imatinib\u2019s pharmacokinetics and elevated CK levels, indicating a possible correlation between specific metabolites and improved treatment response. Individualized monitoring of CK levels and imatinib pharmacokinetics could enhance care for CML patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03675-9","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T07:03:46Z","timestamp":1711523026000},"page":"1061-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring"],"prefix":"10.1007","volume":"80","author":[{"given":"Mervat M.","family":"Omran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel B.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia A.","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa S.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"4","key":"3675_CR1","first-page":"411","volume":"9","author":"HH Ran","year":"2012","unstructured":"Ran HH, Zhang R, Lu XC, Yang B, Fan H, Zhu HL (2012) Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review. Journal of geriatric cardiology: JGC 9(4):411\u2013414","journal-title":"Journal of geriatric cardiology: JGC"},{"issue":"2","key":"3675_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3324\/haematol.11680","volume":"93","author":"A Franceschino","year":"2008","unstructured":"Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C (2008) Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 93(2):317\u2013318","journal-title":"Haematologica"},{"issue":"6","key":"3675_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.leukres.2009.11.002","volume":"34","author":"JK Gordon","year":"2010","unstructured":"Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E (2010) Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 34(6):827\u2013829","journal-title":"Leuk Res"},{"key":"3675_CR4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kek\u00e4le","year":"2015","unstructured":"Kek\u00e4le M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733\u20131740","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"3675_CR5","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s12032-012-0204-1","volume":"29","author":"A Adenis","year":"2012","unstructured":"Adenis A, Bouch\u00e9 O, Bertucci F, Kalbacher E, Fournier C, Cassier P et al (2012) Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Medical oncology (Northwood, London, England) 29(4):3003\u20133008","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"25","key":"3675_CR6","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1056\/NEJMc0708896","volume":"358","author":"N Penel","year":"2008","unstructured":"Penel N, Blay JY, Adenis A (2008) Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 358(25):2746\u20132747","journal-title":"N Engl J Med"},{"issue":"8","key":"3675_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908\u2013916","journal-title":"Nat Med"},{"issue":"1","key":"3675_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13b","volume":"13","author":"C Gambacorti-Passerini","year":"2007","unstructured":"Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E (2007) In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.\u2019 Nature med 13(1):13\u201314. author reply 5\u20136","journal-title":"Nature med"},{"issue":"1","key":"3675_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13a","volume":"13","author":"A Hatfield","year":"2007","unstructured":"Hatfield A, Owen S, Pilot PR (2007) In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.\u2019 Nature med 13(1):13. author reply 5\u20136","journal-title":"Nature med"},{"issue":"4","key":"3675_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1211\/jpp.58.4.0017","volume":"58","author":"SY Saad","year":"2006","unstructured":"Saad SY, Alkharfy KM, Arafah MM (2006) Cardiotoxic effects of arsenic trioxide\/imatinib mesilate combination in rats. J Pharm Pharmacol 58(4):567\u2013573","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"3675_CR11","first-page":"2028","volume":"24","author":"B Dong","year":"2020","unstructured":"Dong B, Chen DF, Bu XH, Qin HB, Xi Y (2020) Effect of imatinib on DOCA-induced myocardial fibrosis in rats through P38 MAPK signaling pathway. Eur Rev Med Pharmacol Sci 24(4):2028\u20132036","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"3675_CR12","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1182\/blood.V104.11.2933.2933","volume":"104","author":"HK Al-Ali","year":"2004","unstructured":"Al-Ali HK, Krahl R, Orth M, Perlowski S, Otto S, Deininger MW et al (2004) Persistently increased creatine kinase levels in patients with chronic myeloid leukemia treated with imatinib correlate with major cytogenetic remission. Blood 104(11):2933","journal-title":"Blood"},{"issue":"9","key":"3675_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3675_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clinical cancer research: an official journal of the American Association for Cancer Research 17(3):406\u2013415","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"7","key":"3675_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-010-1142-7","volume":"90","author":"P Mlejnek","year":"2011","unstructured":"Mlejnek P, Dolezel P, Faber E, Kosztyu P (2011) Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol 90(7):837\u2013842","journal-title":"Ann Hematol"},{"issue":"8","key":"3675_CR16","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","volume":"165","author":"AM Filppula","year":"2012","unstructured":"Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787\u20132798","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3675_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M von Mehren","year":"2011","unstructured":"von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291\u2013299","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3675_CR18","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028","journal-title":"Blood"},{"issue":"8","key":"3675_CR19","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499","journal-title":"Blood"},{"issue":"1","key":"3675_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10428194.2021.1971219","volume":"63","author":"A Bankar","year":"2022","unstructured":"Bankar A, Lipton JH (2022) Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. Leuk Lymphoma 63(1):179\u2013188","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3675_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/bloodadvances.2020002973","volume":"5","author":"A Nasser","year":"2021","unstructured":"Nasser A, Hussein A, Chamba C, Yonazi M, Mushi R, Schuh A et al (2021) Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv 5(5):1403\u20131411","journal-title":"Blood Adv"},{"issue":"10","key":"3675_CR22","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","volume":"114","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Jones D, Kantarjian HM, O\u2019Brien S, Tam C, Koller C et al (2009) Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037\u20132043","journal-title":"Blood"},{"issue":"1","key":"3675_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30(1):48\u201356","journal-title":"Leukemia"},{"issue":"4","key":"3675_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"11","key":"3675_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute 90(11):850\u20138","journal-title":"Journal of the National Cancer Institute"},{"key":"3675_CR26","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood.V110.11.2965.2965","volume":"110","author":"J Hewitt","year":"2007","unstructured":"Hewitt J, Rusnak D, Cox-Kennett N, Larratt L, Turner R (2007) HyperCKemia in CML patients on imatinib mesylate. Blood 110:2965","journal-title":"Blood"},{"issue":"6","key":"3675_CR27","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"key":"3675_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3389\/fonc.2020.01348","volume":"10","author":"MM Omran","year":"2020","unstructured":"Omran MM, Abdelfattah R, Moussa HS, Alieldin N, Shouman SA (2020) Association of the trough, peak\/trough ratio of imatinib, pyridine-N-oxide imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G with imatinib response in Egyptian chronic myeloid leukemia patients. Front Oncol 10:1348","journal-title":"Front Oncol"},{"issue":"5","key":"3675_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","volume":"27","author":"K Titier","year":"2005","unstructured":"Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P et al (2005) Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 27(5):634\u2013640","journal-title":"Ther Drug Monit"},{"issue":"4","key":"3675_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.leu.2402868","volume":"17","author":"C Shimazaki","year":"2003","unstructured":"Shimazaki C, Ochiai N, Uchida R, Fuchida SI, Okano A, Ashihara E et al (2003) Intramuscular edema as a complication of treatment with imatinib. Leukemia 17(4):804\u2013805","journal-title":"Leukemia"},{"issue":"5","key":"3675_CR31","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research 8(5):935\u2013942","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"19","key":"3675_CR32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354(19):2006\u20132013","journal-title":"N Engl J Med"},{"issue":"4","key":"3675_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/bdrc.10030","volume":"69","author":"C Betsholtz","year":"2003","unstructured":"Betsholtz C (2003) Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today 69(4):272\u2013285","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"1","key":"3675_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.1414","volume":"201","author":"Y Zhao","year":"2003","unstructured":"Zhao Y, Haginoya K, Sun G, Dai H, Onuma A, Iinuma K (2003) Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 201(1):149\u2013159","journal-title":"J Pathol"},{"key":"3675_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/960363","volume":"2012","author":"MF Baird","year":"2012","unstructured":"Baird MF, Graham SM, Baker JS, Bickerstaff GF (2012) Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. Journal of nutrition and metabolism 2012:960363","journal-title":"Journal of nutrition and metabolism"},{"key":"3675_CR36","doi-asserted-by":"crossref","unstructured":"Oosthuyse T, Bosch AN (2017) The effect of gender and menstrual phase on serum creatine kinase activity and muscle soreness following downhill running. Antioxidants (Basel, Switzerland). 6(1)","DOI":"10.3390\/antiox6010016"},{"issue":"4","key":"3675_CR37","first-page":"249","volume":"82","author":"JC Cook","year":"1990","unstructured":"Cook JC, Wong E, Haywood LJ (1990) Creatine kinase: race-gender differences in patients hospitalized for suspected myocardial infarction. J Natl Med Assoc 82(4):249\u2013254","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"3675_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1748-1716.1990.tb08823.x","volume":"138","author":"GJ Amelink","year":"1990","unstructured":"Amelink GJ, Koot RW, Erich WB, Van Gijn J, B\u00e4r PR (1990) Sex-linked variation in creatine kinase release, and its dependence on oestradiol, can be demonstrated in an in-vitro rat skeletal muscle preparation. Acta Physiol Scand 138(2):115\u2013124","journal-title":"Acta Physiol Scand"},{"issue":"1","key":"3675_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1365-201x.1999.00481.x","volume":"165","author":"J Komulainen","year":"1999","unstructured":"Komulainen J, Koskinen SO, Kalliokoski R, Takala TE, Vihko V (1999) Gender differences in skeletal muscle fibre damage after eccentrically biased downhill running in rats. Acta Physiol Scand 165(1):57\u201363","journal-title":"Acta Physiol Scand"},{"issue":"4","key":"3675_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/bjsm.28.4.267","volume":"28","author":"LL Smith","year":"1994","unstructured":"Smith LL, Fulmer MG, Holbert D, McCammon MR, Houmard JA, Frazer DD et al (1994) The impact of a repeated bout of eccentric exercise on muscular strength, muscle soreness and creatine kinase. Br J Sports Med 28(4):267\u2013271","journal-title":"Br J Sports Med"},{"issue":"4","key":"3675_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/026404100364965","volume":"18","author":"J Rinard","year":"2000","unstructured":"Rinard J, Clarkson PM, Smith LL, Grossman M (2000) Response of males and females to high-force eccentric exercise. J Sports Sci 18(4):229\u2013236","journal-title":"J Sports Sci"},{"issue":"11 Suppl","key":"3675_CR42","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/00002060-200211001-00007","volume":"81","author":"PM Clarkson","year":"2002","unstructured":"Clarkson PM, Hubal MJ (2002) Exercise-induced muscle damage in humans. Am J Phys Med Rehabil 81(11 Suppl):S52-69","journal-title":"Am J Phys Med Rehabil"},{"issue":"2","key":"3675_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00280-012-2035-3","volume":"71","author":"P Gandia","year":"2013","unstructured":"Gandia P, Arellano C, Lafont T, Huguet F, Malard L, Chatelut E (2013) Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? Cancer Chemother Pharmacol 71(2):531\u2013536","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3675_CR44","first-page":"317","volume":"7","author":"W Zhuang","year":"2018","unstructured":"Zhuang W, Xie JD, Zhou S, Zhou ZW (2018) Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? 7(2):317\u2013324","journal-title":"Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?"},{"issue":"12","key":"3675_CR45","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","volume":"50","author":"N Widmer","year":"2014","unstructured":"Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Lev\u00eaque D et al (2014) Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. European J Cancer (Oxford, England\u202f: 1990) 50(12):2020\u20132036","journal-title":"European J Cancer (Oxford, England : 1990)"},{"key":"3675_CR46","doi-asserted-by":"crossref","unstructured":"Ondecker J, Kordic G, Jordan K (2018) Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST. 11(1)","DOI":"10.1136\/bcr-2018-226647"},{"issue":"2","key":"3675_CR47","first-page":"271","volume":"87","author":"DT Vithanachchi","year":"2021","unstructured":"Vithanachchi DT, Maujean A (2021) A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments 87(2):271\u2013283","journal-title":"A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03675-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:02:20Z","timestamp":1717732940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03675-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3675"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03675-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study according to National Cancer Institute IRB00004025. Written informed consent has been obtained from the subjects to publish this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}